Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

EXTON, Pa., Feb. 27 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and twelve months ended December 31, 2007.

Key events since September 30, 2007 include:

Development:

-- European Orphan Drug Designation received for Camvia(TM) (maribavir);

-- Patient enrollment continued in both phase 3 studies of Camvia in stem

cell and solid organ transplant patients;

-- Prelaunch activities for Camvia accelerated including new medical

affairs and PR initiatives in preparation for the planned 2009 NDA and

MAA filings;

-- Monitoring and follow-up of patients who received HCV-796 in ongoing

phase 2 study continued; evaluation of potential benefits versus risks

to patients is ongoing to understand if and how further clinical

studies are appropriate; and

-- Work continued to optimize manufacturing and scale up for non-toxigenic

C. difficile (NTCD) project in preparation for human clinical trials.

Operational:

-- Net sales of Vancocin(R) were $48 million;

-- Launched new sales and marketing initiatives for Vancocin; and

-- Research and development expenses increased by 305 percent over the

fourth quarter of 2006, primarily driven by investments in Camvia, NTCD

and increased personnel to support clinical momentum.

Financial Results

-- Operating income was $19 million;

-- Increased working capital by $21 million to $594 million;

-- Cash, cash equivalents and short-term investments grew by $32 million

to $584 million; and

-- 12th consecutive quarter of positive cash flow and profitability'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
10. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
11. Aflac Incorporated to Release Third Quarter Results On October 23, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Dennis Thompson HealthDay Reporter ... day, people receive medical implants -- artificial valves, hip ... have been rigorously tested before or after their approval by ... The studies -- conducted by prominent nonprofit groups and ... -- lay the blame for inadequate medical device testing on ...
(Date:9/30/2014)... 30, 2014 Houstonians seeking the latest ... to visit on the Internet. Paul Vitenas, JR. ... respected cosmetic surgeons, has launched a new website to ... of Botox Cosmetic services. The new website ... According to the new website, Botox Cosmetic is a ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Neuromuscular ... people throughout the United States and worldwide. It ... Disease are diagnosed each year, adding to the ... the disease. Approximately 400,000 people in the US ... worldwide. Add to these statistics the 2.4 percent ...
(Date:9/30/2014)... Gummy teeth treatment expert, ... for dark gums. Dark gums are usually considered a ... self-conscious about their smiles. Dr. Farnoosh has pioneered a ... one of the few dental professionals nationwide offering black ... business leaders, high-ranking officials and patients from all over ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Herceptin is the best ... HER2-positive and should remain the standard of care for ... a long-term clinical trial. HER2-positive breast cancers tend ... cancer, according to the Mayo Clinic. For the ... either Herceptin (trastuzumab) or Tykerb (lapatinib) in addition to ...
Breaking Medicine News(10 mins):Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2
... (CLP) at Thomas Jefferson University Hospital, recently received an ... scope of the normal duties of serving as ... American College of Surgeons Commission on Cancer (CoC). ... appointment and is among a national network of over ...
... ... Use Dashboard will provide a single location where an organization can see, at a ... ... 2010 -- Health Care DataWorks , a Technology Company created to commercialize the ...
... finds they are equal to artery-clearing surgery, but another ... -- Both stents and conventional surgery appear to be ... arteries are blocked, according to research presented Friday at ... , However, a second stents-versus-surgery trial, published Thursday in ...
... ... company, has signed a strategic partnership agreement with Medical Insight to complete the ... capability across the healthcare enterprise. , , ... Milwaukee (PRWEB) February 26, 2010 -- ...
... The natural-occurring biopolymer known as chitosan is being put ... the diet of ruminants, according to research carried out ... presence of these antibiotics as additives in the diet ... since 2006, given that their use is linked to ...
... ... ... ... ...
Cached Medicine News:Health News:Jefferson surgeon receives outstanding performance award from American College Of Surgeons 2Health News:HCD Announces Meaningful Use Dashboard for Health Systems 2Health News:Stents May Be Effective Weapon Against Stroke 2Health News:Stents May Be Effective Weapon Against Stroke 3Health News:Stents May Be Effective Weapon Against Stroke 4Health News:TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company 2Health News:TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company 3Health News:Chitosan as alternative to growth-promoting antibiotics for ruminants 2Health News:Chitosan as alternative to growth-promoting antibiotics for ruminants 3Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 2Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 3Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 4Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 5
(Date:9/29/2014)... YORK , Sept. 29, 2014 EU5 ... Summary GlobalData,s new report, "EU5 Capsule ... data on the EU5 Capsule Endoscopy Systems market. The ... (in units) and average prices (in US dollars) within ... and Capsule Endoscopy Workstations. The report also ...
(Date:9/29/2014)... Pharmaceutical Care Management Association (PCMA) President and ... that could reduce prescription fraud and abuse in Medicare ... Opioid Abuse: Fighting Back on Many Fronts ," sponsored ... The briefing featured several government and industry ... fraud. The Centers for Disease Control and Prevention has ...
(Date:9/29/2014)... LAKE CITY , Sept. 29, 2014 /PRNewswire/ ... has scheduled a conference call for investors today ... for the quarter and year ended June 30, ... in participating is (800) 771-7941. Dynatronics ... soft goods and supplies, treatment tables and rehabilitation ...
Breaking Medicine Technology:EU5 Capsule Endoscopy Systems Market Outlook to 2020 2EU5 Capsule Endoscopy Systems Market Outlook to 2020 3PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2
... 2011 Genomic Health, Inc. (Nasdaq: GHDX ) today ... on Wednesday, August 3 at 4:30 p.m. Eastern Time to discuss ... follow the release of the second quarter financial results after market ... To access the live conference call on August 3 at ...
... July 27, 2011 For men facing radical prostatectomy ... not their only concern. In fact, a large number of ... continence among their biggest fears. More than 240,000 men will ... patients of Dr. David Samadi,s, Vice Chairman, Department of Urology, ...
Cached Medicine Technology:Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011 2Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011 3Post Robotic Prostate Surgery Continence and Pelvic Floor Muscles 2Post Robotic Prostate Surgery Continence and Pelvic Floor Muscles 3
Manufactured with large, shatter-resistant Clear Pb leaded acrylic panels which provide a wide field of vision for one or more users. Opaque lower panels are covered in your choice of decorative viny...
... Excellent for patient protection ... erect chest and cervical spine. ... 0.5mm shield. Height adjustable 36" ... sturdy star-leg aluminum base for ...
RayShield Frame Mounted Overhead Lead Acrylic Barriers are offered in a choice of three sizes: 60 cm x 80 cm ( 24" x 32") wide, 60 cm x 50 cm( 24" x 20") wide. Lead acrylic windows of 0.5 mm and 1.0 ...
Ball-and-socket center mount can rotate 360, allowing them to be turned hoirzontally, vertically, or at any angle. Very versatile! Available with or without torso placement contour cutout and in thre...
Medicine Products: